和文論文・著書

英文論文・著書

• Takaaki Fujii, Yuko Nakazawa, Misato Ogino, Sayaka Obayashi, Reina Yajima, Chikako Honda, Hideharu Nakamura, Takaya Makiguchi, Ken Shirabe. Oncological safety of immediate breast reconstruction with skin- or nipple-sparing mastectomy: the value of tumor-to-dermis distance measured by preoperative ultrasonography. World J Surg Oncol. 2021
• Misato Ogino, Takaaki Fujii, Yuko Nakazawa, Toru Higuchi, Yukio Koibuchi, Tetsunari Oyama, Jun Horiguchi, Ken Shirabe. Implications of Topoisomerase (TOP1 and TOP2α) Expression in Patients With Breast Cancer. In Vivo. 2020
• Yuko Nakazawa, Seshiru Nakazawa, Sasagu Kurozumi, Misato Ogino, Yukio Koibuchi, Hiroki Odawara, Tetsunari Oyama, Jun Horiguchi, Takaaki Fujii, Ken Shirabe. The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy. Oncol Lett. 2020
• Takaaki Fujii, Tomoko Hirakata, Sasagu Kurozumi, Shoko Tokuda, Yuko Nakazawa, Sayaka Obayashi, Reina Yajima, Tetsunari Oyama, Ken Shirabe. VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer．In Vivo. 2020
• Takaaki Fujii, Shoko Tokuda, Yuko Nakazawa, Sasagu Kurozumi, Sayaka Obayashi, Reina Yajima, Ken Shirabe. Relationship Between FDG Uptake and the Platelet/lymphocyte Ratio in Patients With Breast Invasive Ductal Cancer. In Vivo. 2020
• Takaaki Fujii, Shoko Tokuda, Yuko Nakazawa, Sasagu Kurozumi, Sayaka Obayashi, Reina Yajima, Ken Shirabe. Implications of Low Serum Albumin as a Prognostic Factor of Long-term Outcomes in Patients With Breast Cancer. In Vivo. 2020
• Takaaki Fujii, Shoko Tokuda, Yuko Nakazawa, Sasagu Kurozumi, Sayaka Obayashi, Reina Yajima, Ken Shirabe. Eribulin Suppresses New Metastases in Patients With Metastatic Breast Cancer. In Vivo. 2020
• Misato Ogino, Takaaki Fujii, Yuko Nakazawa, Toru Higuchi, Yukio Koibuchi, Tetsunari Oyama, Jun Horiguchi, Ken Shirabe. Implications of Topoisomerase (TOP1 and TOP2α) Expression in Patients With Breast Cancer. In Vivo. 2020
• Keiko Yanai, Takaaki Fujii, Jun Horiguchi, Yuko Nakazawa, Sasagu Kurozumi, Sayaka Obayashi, Reina Yajima, Ken Shirabe. Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer. BMC Cancer. 2020
• Sasagu Kurozumi, Mansour Alsaleem, Cíntia J. Monteiro, Kartikeya Bhardwaj, Stacey E. P. Joosten, Takaaki Fujii, Ken Shirabe, Andrew R. Green, Ian O. Ellis, Emad A. Rakha, Nigel P. Mongan, David M. Heery, Wilbert Zwart, Steffi Oesterreich, Simon J. Johnston. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. Breast Cancer Res. 2020
• Sasagu Kurozumi, Chitra Joseph, Sultan Sonbul, Sami Alsaeed, Yousif Kariri, Abrar Aljohani, Sara Raafat, Mansour Alsaleem, Angela Ogden, Simon J Johnston, Mohammed A Aleskandarany, Takaaki Fujii, Ken Shirabe, Carlos Caldas, Ibraheem Ashankyty, Leslie Dalton, Ian O Ellis, Christine Desmedt, Andrew R Green, Nigel P Mongan, Emad A Rakha. A key genomic subtype associated with lymphovascular invasion in invasive breast cancer. Br J Cancer. 2019
• Sasagu Kurozumi, Hiroshi Matsumoto, Masafumi Kurosumi, Kenichi Inoue, Takaaki Fujii, Jun Horiguchi, Ken Shirabe, Tetsunari Oyama, Hiroyuki Kuwano. Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis. Oncol Lett. 2019
• Sasagu Kurozumi, Kenichi Inoue, Hiroshi Matsumoto, Takaaki Fujii, Jun Horiguchi, Tetsunari Oyama, Masafumi Kurosumi, Ken Shirabe. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer. Sci Rep. 2019
• Sasagu Kurozumi, Yuri Yamaguchi, Hiroshi Matsumoto, Masafumi Kurosumi, Shin-ichi Hayashi, Takaaki Fujii, Jun Horiguchi, Ken Shirabe, Kenichi Inoue. Utility of Ki67 labeling index, cyclin D1 expression, and ER-activity level in postmenopausal ER-positive and HER2-negative breast cancer with neoadjuvant chemo-endocrine therapy. PLoS One. 2019
• Sasagu Kurozumi, Kenichi Inoue, Hiroshi Matsumoto, Takaaki Fujii, Jun Horiguchi, Tetsunari Oyama, Masafumi Kurosumi, Ken Shirabe. Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer. Sci Rep. 2019
• Fujii T, et al. Relationship Between FDG Uptake and Neutrophil/Lymphocyte Ratio in Patients with Invasive Ductal Breast Cancer. Anticancer Res. 2018
• Fujii T, et al. Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01). Anticancer Res 2018
• Kurozumi S, et al. Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer. Med Mol Morphol. 2018
• Toda H, Kurozumi S, et al. Molecular pathogenesis of triple-negative breast cancer based on microRNA expression signatures: antitumor miR-204-5p targets AP1S3. J Hum Genet. 2018
• Kurozumi S, et al. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer. PLoS One. 2018
• Kurozumi S, et al. Clinicopathological and prognostic significance of Ras association and pleckstrin homology domains 1 (RAPH1) in breast cancer. Breast Cancer Res Treat. 2018
• Makiguchi T, Nakamura H, Fujii T, Yokoo S. Quantitative assessment and risk factors for nipple-areolar complex malposition after nipple-sparing mastectomy. Breast Cancer. 2018
• Kurozumi S, et al. Clinical and biological roles of Kelch-like family member 7 in breast cancer: a marker of poor prognosis. Breast Cancer Res Treat. 2018
• Fujii T, et al. Implication of atypical supraclavicular F18-fluorodeoxyglucose uptake in patients with breast cancer: Relationship between brown adipose tissue and breast cancer progression. Oncology Letters 2017
• Obayashi S, et al. Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients. Int J Oncol 2017
• Kurozumi S, et al. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Med Mol Morphol 2017
• Kurozumi S, et al. Power of PgR expression as a prognostic factor for ER-positive/HER2-negatiev breast cancer patients at intermediate risk classified by the Ki67 labeling index. BMC Cancer 2017.
• Kurozumi S, et al. Recent in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. J Hum Genet 2017.
• Fujii T, et al. Clinicopathological Features of Ductal Carcinoma In Situ from 18F-FDG-PET Findings. Anticancer Res 2017.
• Kurozumi S, Fujii T, Matsumoto H, Inoue K, Kurosumi M, Horiguchi J, Kuwano H. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Med Mol Morphol. 2017
• Fujii T, et al. 18F-fluorodeoxyglucose uptake as predictor for invasion in preoperatively diagnosed breast ductal carcinoma in situ: Significance in cases without mass formation Mol Clin Oncol 2017
• Fujii T, et al. A case of subareolar abscess in the male breast: Usefulness of MRI for diagnosis. International Journal of Case Reports and Images 2017
• Yajima R, et al. Tumor-infiltrating CD45RO+ memory cells are associated with a favorable prognosis breast cancer. Breast Cancer 2016.
• Kurozumi S, et al. HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Res Treat 2016.
• Kurozumi S, et al. Prognostic value of the ubiquitin ligase carboxyl terminus of the Hsc70-interacting protein in postmenopausal breast cancer. Cancer Med 2016.
• Fujii T, et al. Clinicopathological features of cases with primary breast cancer not identified by 18F-FDG-PET. Anticancer Res 2016.
• Fujii T, et al. Clincal significance of 18F-FDG-PET in invasive lobular carcinoma. Anticancer Res 2016.
• Fujii T, et al. Implication of F18-fluorodeoxyglucose uptake of affected axillary lymph nodes in cases with differentiated thyroid cancer. Mol Clin Oncol 2016.
• Fujii T, et al. Implications of long-term indwelling of tissue expander in breast reconstruction: risk of expander rupturing. Anticancer Res 2016.
• Fujii T, et al. Implication of F18-fluorodeoxyglucose uptake of affected axillary lymph nodes in cases with breast cancer. Anticancer Res 2016.
• Fujii T, et al. Prediction of extracapsular invasion at metastatic sentinel nodes and non-sentinel lymph nodal metastases by FDG-PET in cases with breast cancer. Anticancer Res 2016
• Fujii T, et al. Anticancer effect of rapamycin on MCF-7 via downregulation of VEGF expression. In Vitro Cell Dev Biol Anim 2016.
• Fujii T, et al. Cystic parathyroid adenoma with MIBI scan-negative PHPT: Usefulness of Gamma camera. Int J Case Rep Imag 2016.
• Kurozumi S, et al. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab. BMC Cancer 2015.
• Fujii T, et al. Impact of vascular invasion of a primary tumor as a strong risk factor for disease recurrence in patients with node-positive breast cancer. Am Surg 2015
• Fujii T, et al. Significance of lymphatic invasion combined with size of primary tumor for predicting sentinel lymph node metastasis in patients with breast cancer. Anticancer Res 2015
• Fujii T, et al. Implication of duration of clinical presentation on tumor progression and the short-term recurrence in patients with early breast cancer. Mol Clin Oncol 2015
• Yajima R, et al. Prognostic value of extracapsular invasion of axillary lymph nodes combined with peritumoral vascular invasion in patients with breast cancer. Ann Surg Oncol 2015.